HLX-60

N/A

Report date: 2022/11/20 17:22:28

Base Information

Drug NameHLX-60
Drug Alias NameHLX-60
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTransforming growth factor beta activator LRRC32 modulators
TargetsTransforming growth factor beta activator LRRC32
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A